3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 1
3
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
5
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Interventions
Carboplatin
273
Paclitaxel
267
Gemcitabine
244
Bevacizumab
226
Cisplatin
218
pembrolizumab
214
Docetaxel
210
Pemetrexed
162
Capecitabine
148
Fluorouracil
129
Oxaliplatin
121
Cyclophosphamide
121
Nivolumab
112
Dexamethasone
100
Trastuzumab
89
Leucovorin
87
Cetuximab
85
Rituximab
83
Irinotecan
82
Injections
81
Erlotinib Hydrochloride
70
Prednisone
68
Doxorubicin
68
Temozolomide
67
atezolizumab
65
Bortezomib
65
Ipilimumab
64
Fulvestrant
59
Radiotherapy
54
Drug Therapy
51
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
INDUSTRY
×
ARQ531
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled